BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35798286)

  • 21. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
    Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
    PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
    Sun Z; Zhang Y; Cao D; Wang X; Yan X; Li H; Huang L; Qu X; Kong C; Qin H; Wang M; Xu W; Liang L
    Drug Deliv; 2018 Nov; 25(1):1746-1755. PubMed ID: 30394118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.
    Pan M; Wang F; Nan L; Yang S; Qi J; Xie J; Shao S; Zou H; Wang M; Sun F; Zhang J
    Cancer Immunol Immunother; 2023 Apr; 72(4):969-984. PubMed ID: 36227341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model.
    Lee EJ; Yang JH; Yang HJ; Cho CK; Choi JG; Chung HS
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.
    Fetse J; Zhao Z; Liu H; Mamani UF; Mustafa B; Adhikary P; Ibrahim M; Liu Y; Patel P; Nakhjiri M; Alahmari M; Li G; Cheng K
    J Med Chem; 2022 Sep; 65(18):12002-12013. PubMed ID: 36067356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
    Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
    Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.